Immunological and pathophysiological mechanisms in IBD (Crohn's Disease, Ulceritive Colitis)
Bethesda, MD – (June 22, 2004) The American Physiological Society (APS) announces it is sponsoring a translational research conference entitled "Immunological and Pathophysiological Mechanisms in Inflammatory Bowel Diseases" from Sept. 8-11, 2004 in Snowmass, Colorado.
The keynote lecture, "IBD: Light at the End of the Tunnel?" will be delivered by Daniel Podolsky, M.D., professor of medicine at Harvard Medical School and chief of the gastrointestinal unit at the affiliated Massachusetts General Hospital.
The final panel of the meeting, featuring researchers from the Mayo Clinic, Cedars-Sinai Medical Center, University of Barcelona, Spain, and University of Bologna, Italy, will describe new therapeutic strategies in the treatment of IBD.
In addition to evening sessions involving research poster presentations, the meeting will feature symposia led by noted researchers on the following subjects:
- Genetics of IBD
- Role of the immune system in intestinal inflammation: Who are the players and what do they do?
- Innate immune responses in IBD: Role of the vasculature
- Cytokines, chemokines and mediators of chronic inflammation
- Bacterial/host interactions in the pathogenesis of IBD
- New therapeutic strategies in the treatment of IBD
According to co-organizers Matthew Grisham, of Louisiana State University, Shreveport and Fabio Cominelli, of the University of Virginia, the IBD conference is the "first in a series of translational, that is, bench to bedside, conferences to be sponsored by APS aimed at bringing together internationally recognized scientists and clinicians as well as promising young investigators" in a variety of physiological subjects.
Speakers and other participants, many of whom will be presenting poster abstracts, come from all over world, and include researchers and students from the graduate through senior research/faculty level.
Abstracts already have been received from researchers working in Australia, Canada, Germany, Greece, Israel, Italy, Japan, the Netherlands, Puerto Rico, and Spain, as well as throughout the U.S.
Over the four days of sessions, participants will gain an in-depth understanding of the latest developments in research on the underlying mechanisms responsible for experimental and clinical IBD.
Reflecting the "translational" nature of the meetings sponsored by the American Physiological Society, clinical, pharmaceutical and biotech researchers will highlight novel IBD therapeutic strategies.
Media registration and information
Full information about the conference, including the detailed schedule, is at: http://www.the-aps.org/meetings/aps/snowmass/index.htm
Media wishing to attend part or all of the conference in person, and to arrange interviews in advance, should call or email APS communications contacts:
APS website www.the-aps.org; next APS conference: "Exercise"
For more information about APS, its journals and publications, extensive educational and mentoring activities and other meetings, go to the APS website.
The "Press Room" section offers access to press releases and abstracts on research presented at past meetings as well as research reported in APS journals.
The next APS conference, "Integrative Biology of Exercise," is scheduled for October 6-9, 2004 in Austin, Texas. Information is available at:
The American Physiological Society (APS) was founded in 1887 to foster basic and applied science, much of it relating to human health. The Bethesda, MD-based Society has more than 10,000 members and publishes over 3,800 articles in its 14 peer-reviewed journals every year.
In May 2004, APS received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring (PAESMEM).
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
I do not think there is any other quality so essential to success of any kind as the quality of perseverance. It overcomes almost everything, even nature.
-- John D. Rockefeller